Bài kiểm tra có liên kết hướng dẫn · Trung bình Cấp độ

AI trong bài kiểm tra bệnh gan và gan

Kiểm tra tính điểm bệnh lý gan, nghiên cứu siêu âm, mô hình nguy cơ cấy ghép, phạm vi chứng nhận của FDA và đánh giá chuyên môn.

Đường dẫn hướng dẫn liên quanAI trong bệnh gan và bệnh gan
Câu hỏi 1 của 8

For what setting did FDA qualify AIM-NASH as a drug-development tool?

Xem trước mọi câu hỏi8 câu hỏi

Câu trả lời và giải thích xuất hiện khi bạn làm bài kiểm tra.

  1. For what setting did FDA qualify AIM-NASH as a drug-development tool?
    • Diagnosing all liver diseases from a blood test
    • Setting transplant priority in every country
    • Scoring liver-biopsy features in MASH clinical trials
    • Replacing liver biopsy with ultrasound
  2. Who makes the final interpretation of an AIM-NASH biopsy score?
    • The AI tool alone
    • The pathologist after reviewing the whole slide and AI output
    • The trial sponsor
    • A transplant coordinator
  3. Why should ultrasound and biopsy AI results be treated as different tasks?
    • Every imaging method measures the same tissue directly
    • A biopsy model automatically validates ultrasound
    • Ultrasound tools never use AI
    • They use different inputs and reference standards
  4. What did the GEMA-AI study estimate?
    • A waitlist outcome estimate for transplant candidates using clinical variables
    • A histology grade for steatosis in biopsy images
    • A radiology score for liver ultrasound texture
    • A classification of cancer-signal origin in blood
  5. Does a research model automatically become a transplant allocation rule?
    • Yes, once it has an external test set
    • Yes, when it uses the same lab variables
    • No; allocation requires policy and multidisciplinary review
    • No, because prediction models cannot use lab results
  6. Which liver-biopsy features does AIM-NASH score?
    • Kidney filtration, blood pressure and sodium only
    • Steatosis, inflammation and fibrosis
    • Thyroid shape, margin and echogenicity
    • Tumor stage and medication response
  7. What should a liver imaging team check before using an AI fibrosis score?
    • That the model was trained on any organ image
    • Only whether the report is short
    • Whether a transplant list is available
    • That the model was validated for the relevant imaging task and patient group
  8. What remains central in transplant allocation decisions?
    • Policy, equity, organ availability and transplant-team review
    • The highest model score alone
    • An ultrasound image without other information
    • A model vendor’s ranking